NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Price Target & More

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced its quarterly earnings data on Friday, May, 4th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.10. The company earned $144.40 million during the quarter, compared to the consensus estimate of $144.01 million. Ionis Pharmaceuticals had a negative net margin of 2.00% and a negative return on equity of 3.06%. The company's quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.03 EPS. View Ionis Pharmaceuticals' Earnings History.

11 equities research analysts have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their predictions range from $18.00 to $75.00. On average, they expect Ionis Pharmaceuticals' share price to reach $53.00 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.

Ionis Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 12,158,108 shares, an increase of 15.8% from the April 30th total of 10,497,036 shares. Based on an average trading volume of 1,696,916 shares, the short-interest ratio is currently 7.2 days. Approximately 9.8% of the shares of the company are sold short. View Ionis Pharmaceuticals' Current Options Chain.

Some companies that are related to Ionis Pharmaceuticals include Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX) and SAGE Therapeutics (SAGE).

Press coverage about IONS stock has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of 0.17 on Accern's scale. They also assigned news coverage about the company an impact score of 46.34 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Ionis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BB Biotech AG (6.79%), BlackRock Inc. (5.52%), Baillie Gifford & Co. (4.99%), OppenheimerFunds Inc. (2.29%), Pinnacle Associates Ltd. (0.99%) and American Century Companies Inc. (0.94%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., JPMorgan Chase & Co., Van ECK Associates Corp, Pinnacle Associates Ltd., BlackRock Inc., Fiera Capital Corp, Altrinsic Global Advisors LLC and A.R.T. Advisors LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

IONS stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, BB Biotech AG, Scout Investments Inc., Sector Gamma AS, Carillon Tower Advisers Inc., OppenheimerFunds Inc., UBS Group AG and Millennium Management LLC. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $42.95.

Ionis Pharmaceuticals has a market capitalization of $5.29 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.